Leading experts from around the U.S. will share their research on pancreatic cancer at a foundational and translational research symposium on Thursday, July 20 from 9 a.m. to 7 p.m. at the Harry D. McGovern Alumni Center at North Dakota State University, 1241 N. University Drive.
Graduate students and post-doctoral research fellows will provide poster presentations regarding their pancreatic cancer research. Leading experts in the field will share their latest research discoveries that could impact treatment for pancreatic and other cancers. An estimated 64,000 new cases of pancreatic cancer are expected in the U.S. in 2023. According to the American Cancer Society, the five-year survival rate for pancreatic cancer is 12 percent.
Invited event guest speakers include:
- Sandro da Rocha, Ph.D., Professor, Director of Pharmaceutical Engineering, Virginia Commonwealth University - Remodeling the Lung Tumor Microenvironment with Locally Administered Immunochemotherapies
- Igor Roninson, Ph.D., Professor, Director, Center for Targeted Therapeutics College of Pharmacy, University of South Carolina - Targeting Transcriptional Reprogramming for Cancer Therapy
- Luke Theogarajan, Ph.D., Professor and Vice-Chair, Electrical and Computer Engineering, University of California Santa Barbara - Cell and Lattice-Based Modeling for Cancer Biology
- Sudipta Seal, Ph.D., Professor and Chair, Materials Science and Engineering, University of Central Florida Orlando - Development of long-lasting nanozymes for pathogen deactivation
- Tatiana Bronich, Ph.D., Associate Dean, Bouvé College of Health Sciences, Dean, School of Pharmacy and Pharmaceutical Sciences, Northeastern University - Engineering of soft nanomaterials for combination cancer therapy
- Randal Brand, MD, Professor of Medicine, Director, GI Malignancy Early Detection, Diagnosis & Prevention Program, University of Pittsburgh Medical Center - Current Status of Early Detection of Pancreatic Adenocarcinoma
- Michael A. (Tony) Hollingsworth, Ph.D., Associate Director for Basic Research, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center Omaha - Immunosuppression in pancreatic cancer
- Pradeep Dhal, Ph.D., Senior R & D Director within Early Development Synthetics Platform organization, Sanofi Global Research and Development Bridgewater, New Jersey - Antibody-Drug Conjugates as Targeted Cancer Therapies: Recent Developments in Linker and Conjugation Chemistries
For program details, visit https://www.ndsu.edu/centers/pancreaticcancer/symposium/
The symposium is coordinated by the Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer at NDSU. The Center was established with support from the National Institute of General Medical Sciences, under the Center of Biomedical Research Excellence (COBRE) program of the National Institutes of Health, grant 2P20GM109024.
Sanku Mallik, professor of pharmaceutical sciences, and Sathish Venkatachalem, associate professor of pharmaceutical sciences, lead the Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer. A competitive grant totaling more than $16 million from NIH funds the first disease-specific research center at NDSU since 2016.
A lack of early symptoms, short survival time and resistance to therapy are hallmarks of pancreatic cancer. The NDSU Center’s research is aimed at early diagnosis and treatment of this deadly disease.
As a student focused, land grant, research university, we serve our citizens.